Fig. 2From: Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomesThe risk of poor COVID-19 clinical outcome with ACEI/ARBs compared to Non-ACEI/ARBsBack to article page